Biotech Investors & VC Firms

2475 firms in this list, with a median first check of $500K. 505 of them lead rounds. Generated from verified public data and updated continuously.

Fund	FoxScore	HQ	Invests	Stage	Check	CRM
RE redalpine PNALBCDG28 people · Leads rounds	88🔒	Zug	CH	Seed–Growth	$108K – $2.2M	+ Add to CRM
PH PharmStars Ventures NFSPAZAM24 people · Follows rounds	88🔒	Boston	US	Pre-Seed–Seed	—	+ Add to CRM
TH The Engine Ventures ADIRJMMK25 people · Follows rounds	88🔒	Cambridge	US	Pre-Seed–Series A	—	+ Add to CRM
B2 b2venture AGCSCSFS36 people · Follows rounds	88🔒	Berlin	DE	Pre-Seed–Series B	$270K – $5.4M	+ Add to CRM
WO Women's Equity Lab SAASCFEO35 people · Follows rounds	88🔒	Victoria	CA	Pre-Seed–Seed	$18K – $55K	+ Add to CRM
LI LIFTT GTSBAMAB36 people · Leads rounds	88🔒	Torino	IT	Pre-Seed–Growth	—	+ Add to CRM
AN Angel Physicians Fund MBASAKAS44 people · Leads rounds	88🔒	—	US	Pre-Seed–Series A	—	+ Add to CRM
DE Deepbridge Capital IWAHDBGG25 people	88🔒	Chester	GB	Seed–Series A	—	+ Add to CRM
EN Endurance28 CVCCAMCD42 people	88🔒	San Francisco	US	Pre-Seed–Seed	—	+ Add to CRM
SI Siddhi Capital SFASMFSP29 people	88🔒	Meridian	US	Growth	—	+ Add to CRM
GE GENERAL INCEPTION PCVCBCBN42 people · Follows rounds	88🔒	Palo Alto	US	Pre-Seed–Seed	—	+ Add to CRM
BR Breyer Capital JBBLDBLG7 people · Leads rounds	88🔒	Austin	US	Pre-Seed–Series A	$500K – $10M	+ Add to CRM
CO Colle Capital Partners VGAMCMLF28 people · Leads rounds	88🔒	New York	US	Pre-Seed–Series A	$500K – $2M	+ Add to CRM
AT ATEL Ventures SRBBJRMA15 people · Follows rounds	88🔒	San Francisco	US	Seed–Late Stage	—	+ Add to CRM
NV NV NOM AVAWBBBP27 people	88🔒	Groningen	NL	Seed–Growth	—	+ Add to CRM
IL Illumina Ventures NNNNA'A"40 people · Follows rounds	88🔒	Foster City	US	Seed–Series A	—	+ Add to CRM
AM Ampersand DQEBRAMP36 people	88🔒	Boston	US	Growth	—	+ Add to CRM
TH The Column Group PSTKCDDV38 people · Follows rounds	88🔒	San Francisco	US	Pre-Seed–Late Stage	$30M	+ Add to CRM
TW Two Sigma Ventures CDJRDALG26 people · Leads rounds	88🔒	New York	US	Seed–Series B	$2M – $15M	+ Add to CRM
LI Lightstone Ventures HPCGCIHS31 people · Leads rounds	88🔒	Portola Valley	US	Pre-Seed–Series C	—	+ Add to CRM
S3 S32 ACAHBMMP30 people · Follows rounds	88🔒	Palo Alto	US	Series A–Late Stage	—	+ Add to CRM
SA Sanofi Ventures CDJPLCPH20 people · Leads rounds	88🔒	Cambridge	US	Seed–Series B	$5M	+ Add to CRM
HI Hitachi Ventures AGGSJSPB32 people · Follows rounds	88🔒	Munich	DE	Seed–Growth	—	+ Add to CRM
ME Medicxi FDGMGPGZ38 people · Follows rounds	88🔒	London	GB	Seed–Series B	—	+ Add to CRM

redalpine

ZugSeed–Growth$108K – $2.2M

PNALBCDG28 people

PharmStars Ventures

BostonPre-Seed–Seed

NFSPAZAM24 people

The Engine Ventures

CambridgePre-Seed–Series A

ADIRJMMK25 people

b2venture

BerlinPre-Seed–Series B$270K – $5.4M

AGCSCSFS36 people

Women's Equity Lab

VictoriaPre-Seed–Seed$18K – $55K

SAASCFEO35 people

LIFTT

TorinoPre-Seed–Growth

GTSBAMAB36 people

Angel Physicians Fund

Pre-Seed–Series A

MBASAKAS44 people

Deepbridge Capital

ChesterSeed–Series A

IWAHDBGG25 people

Endurance28

San FranciscoPre-Seed–Seed

CVCCAMCD42 people

Siddhi Capital

MeridianGrowth

SFASMFSP29 people

GENERAL INCEPTION

Palo AltoPre-Seed–Seed

PCVCBCBN42 people

Breyer Capital

AustinPre-Seed–Series A$500K – $10M

JBBLDBLG7 people

Colle Capital Partners

New YorkPre-Seed–Series A$500K – $2M

VGAMCMLF28 people

ATEL Ventures

San FranciscoSeed–Late Stage

SRBBJRMA15 people

NV NOM

GroningenSeed–Growth

AVAWBBBP27 people

Illumina Ventures

Foster CitySeed–Series A

NNNNA'A"40 people

Ampersand

BostonGrowth

DQEBRAMP36 people

The Column Group

San FranciscoPre-Seed–Late Stage$30M

PSTKCDDV38 people

Two Sigma Ventures

New YorkSeed–Series B$2M – $15M

CDJRDALG26 people

Lightstone Ventures

Portola ValleyPre-Seed–Series C

HPCGCIHS31 people

S32

Palo AltoSeries A–Late Stage

ACAHBMMP30 people

Sanofi Ventures

CambridgeSeed–Series B$5M

CDJPLCPH20 people

Hitachi Ventures

MunichSeed–Growth

AGGSJSPB32 people

Medicxi

LondonSeed–Series B

FDGMGPGZ38 people

Data sourced from public filings and firms' own websites — see our methodology.